PegBio Co., Ltd. (the Company, stock code: 2565) announced that on 28 October 2025, an application was filed to voluntarily dissolve its non-wholly-owned subsidiary, Shanghai Maiji Biotech Co., Ltd. (Shanghai Maiji). Established on 26 June 2017, Shanghai Maiji was engaged in the research and development of GLP-2, a peptide hormone involved in intestinal functions and metabolism.

According to a shareholders’ resolution dated 11 October 2025, Shanghai Maiji is being dissolved to allow the Company to focus on its core business and streamline operations. The Company stated that the dissolution is not expected to adversely affect its operations or financial position.

Additionally, in line with the listing rules, updated information was provided regarding Dr. Michael Min XU, who serves as the Chairman, an executive director, and the general manager of the Company, as well as the executive director of Shanghai Maiji. The Company confirmed that no other information needs to be brought to the attention of its shareholders.